Form 4: Phibro Animal Health CEO Sells Shares Under 10b5-1 Plan

Phibro Animal Health's President and CEO, Jack Bendheim, and BFI Co., LLC, sold a total of 27,845 shares of Class A Common Stock in pre-planned transactions.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• The sales were conducted under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On January 21, 2026, 14,687 shares were sold at a weighted average price of $41.6782 per share.
• On January 22, 2026, two separate transactions occurred: 11,875 shares were sold at a weighted average price of $41.9086 per share, and 1,283 shares were sold at a weighted average price of $42.6774 per share.
• Following these transactions, Jack Bendheim directly holds 16,840 shares, and BFI Co., LLC indirectly holds 16,680 shares.
• Mr. Bendheim disclaims beneficial ownership of the securities held by BFI except to the extent of his pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sale of shares by the CEO and a 10% owner is generally a negative signal. However, the execution under a pre-planned Rule 10b5-1 trading plan reduces the severity of the negative sentiment, as it suggests the sales are for personal financial planning rather than a reaction to new, adverse company information.

Positives

• The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were not based on new, non-public information.

Negatives

• Significant insider sales by the President and CEO, a Director, and a 10% owner, could be perceived as a lack of confidence in the company's future prospects or that the stock is fully valued.
• A total of 27,845 shares were sold across three transactions.

Future Outlook

NA

Management Comments

• Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the insider sales as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.

Key Dates

Recommendation

While insider sales by a CEO and 10% owner are typically a negative signal, the fact that these sales were executed under a pre-planned Rule 10b5-1 trading plan mitigates the immediate concern that the sales are based on new, adverse information. Investors should monitor future filings and company performance, but this Form 4 alone does not warrant a strong sell recommendation. A "hold" position is appropriate to observe further developments.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, Insider Sales, Form 4, Rule 10b5-1, Class A Common Stock, CEO, Director, 10% Owner